MX340819B - Formulacion oral de inhibidores de quinasa. - Google Patents

Formulacion oral de inhibidores de quinasa.

Info

Publication number
MX340819B
MX340819B MX2012014982A MX2012014982A MX340819B MX 340819 B MX340819 B MX 340819B MX 2012014982 A MX2012014982 A MX 2012014982A MX 2012014982 A MX2012014982 A MX 2012014982A MX 340819 B MX340819 B MX 340819B
Authority
MX
Mexico
Prior art keywords
patients
formulations
fak
peg
bioactive compounds
Prior art date
Application number
MX2012014982A
Other languages
English (en)
Other versions
MX2012014982A (es
Inventor
Xian Chen Andrew
J Tsai Yali
Original Assignee
Poniard Pharmaceuticals Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc * filed Critical Poniard Pharmaceuticals Inc *
Publication of MX2012014982A publication Critical patent/MX2012014982A/es
Publication of MX340819B publication Critical patent/MX340819B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Abstract

La invención se dirige a formulaciones de compuestos bioactivos de solubilidad limitada en agua, los inhibidores de quinasa de adhesión focal (FAK) de la clase 2,4-diaminopiridina, adaptados para administración oral a pacientes. Las formulaciones son autoemulsionantes en el tracto gastrointestinal de los pacientes, proporcionando una absorción y biodispoibilidad mejorada de los compuestos bioactivos como dispersiones o emulsiones en una base oleosa. Por ejemplo, los ésteres de glicerol PEG-ilado se pueden utilizar como el aceite, junto con un tensioactivos tales como lecitina y succinato de TEPG y solubilizantes tales como PEG 400 para proporcionar formulaciones orales útiles para administración a pacientes que tengan una mala condición, en donde la inhibición de FAK está indicada medicamente, tal como cáncer o artritis.
MX2012014982A 2010-06-29 2011-06-28 Formulacion oral de inhibidores de quinasa. MX340819B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35969410P 2010-06-29 2010-06-29
PCT/US2011/042162 WO2012006081A1 (en) 2010-06-29 2011-06-28 Oral formulation of kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2012014982A MX2012014982A (es) 2013-07-03
MX340819B true MX340819B (es) 2016-07-26

Family

ID=45441513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014982A MX340819B (es) 2010-06-29 2011-06-28 Formulacion oral de inhibidores de quinasa.

Country Status (10)

Country Link
US (1) US9375402B2 (es)
EP (1) EP2588081A4 (es)
JP (1) JP5936609B2 (es)
CN (1) CN103313697B (es)
AU (1) AU2011276552B2 (es)
CA (1) CA2803004A1 (es)
MX (1) MX340819B (es)
NZ (1) NZ604583A (es)
WO (1) WO2012006081A1 (es)
ZA (1) ZA201300009B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103534240B (zh) 2011-02-17 2015-12-09 癌症疗法Crc私人有限公司 选择性fak抑制剂
EP2675793B1 (en) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Fak inhibitors
IN2014MN02213A (es) 2012-05-10 2015-07-10 Painreform Ltd

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) * 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ATE417608T1 (de) 2000-10-11 2009-01-15 Cephalon Inc Arzneizusammensetzungen enthaltend modafinilverbindungen
AR040456A1 (es) 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
US20080119515A1 (en) * 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
CN101119976B (zh) 2005-02-18 2010-12-22 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯氨基)嘧啶氧化物衍生物
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP2012753A2 (en) 2006-04-28 2009-01-14 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
DK2046292T3 (da) * 2006-07-21 2010-06-07 Novartis Ag Formuleringer for benzimidazolylpyridylethere
WO2008115369A2 (en) * 2007-03-16 2008-09-25 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
US8569298B2 (en) 2008-06-17 2013-10-29 Astrazeneca Ab Pyridine compounds
CN102648197A (zh) 2009-08-12 2012-08-22 铂雅制药公司 促进细胞凋亡和抑制转移的方法
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
CA2803004A1 (en) 2012-01-12
EP2588081A4 (en) 2014-12-10
AU2011276552A1 (en) 2013-01-10
EP2588081A1 (en) 2013-05-08
ZA201300009B (en) 2013-09-25
WO2012006081A1 (en) 2012-01-12
US9375402B2 (en) 2016-06-28
AU2011276552B2 (en) 2015-09-03
NZ604583A (en) 2015-04-24
CN103313697A (zh) 2013-09-18
MX2012014982A (es) 2013-07-03
CN103313697B (zh) 2016-06-01
US20140206692A1 (en) 2014-07-24
JP2013529686A (ja) 2013-07-22
JP5936609B2 (ja) 2016-06-22

Similar Documents

Publication Publication Date Title
MX2009013804A (es) Inhibidores novedosos de transcriptasa inversa de vih.
GT201300159A (es) Composiciones y metodos para modular el fxr
EA200900213A1 (ru) Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич
GT201400196A (es) Compuestos de heterociclilo
GEP20125459B (en) Compounds for inhibiting mitotic progression
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
WO2012032415A3 (en) Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
HN2008001666A (es) Derivados acidos de cicloalquilamino
UY30681A1 (es) Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos.
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
EA201101435A1 (ru) Имидазотиадиазолы для применения в качестве ингибиторов киназ
UA108640C2 (uk) Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
DOP2012000264A (es) Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
WO2008011117A3 (en) Antiviral protease inhibitors
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
MX2010005714A (es) Compuestos de piridina.
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
AR063027A1 (es) Derivados de sulfonamida
AR082660A1 (es) Composiciones farmaceuticas para el tratamiento de enfermedades respiratorias e inflamatorias

Legal Events

Date Code Title Description
FG Grant or registration